skip to Main Content
stylized drawing of microscope

TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here.

Why this news is important:

  • Zucara has achieved the development milestones required to secure the remaining funds available from its previously announcedUS$21 million Series A Financing.
  • Zucara plans to file an investigational new drug (“IND”) application for a Phase 2 trial by year end, with initiation of first patient dosing expected in Q1 2023.
  • ZT-01 has the potential to become the first therapeutic designed to prevent hypoglycemia in people with Type 1 diabetes.
Back To Top